These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15172406)

  • 21. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
    Ferrari R;
    Arch Intern Med; 2006 Mar; 166(6):659-66. PubMed ID: 16567606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alcohol consumption, atherosclerotic progression, and prognosis among patients with coronary artery bypass grafts.
    Mukamal KJ; Girotra S; Mittleman MA
    Am Heart J; 2006 Feb; 151(2):368-72. PubMed ID: 16442902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials.
    Hasdai D; Topol EJ; Kilaru R; Battler A; Harrington RA; Vahanian A; Ohman EM; Granger CB; Van de Werf F; Simoons ML; O'connor CM; Holmes DR
    Am Heart J; 2003 Jan; 145(1):73-9. PubMed ID: 12514657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
    Tokmakova MP; Skali H; Kenchaiah S; Braunwald E; Rouleau JL; Packer M; Chertow GM; Moyé LA; Pfeffer MA; Solomon SD
    Circulation; 2004 Dec; 110(24):3667-73. PubMed ID: 15569840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of blood pressure measured during hospitalization after acute myocardial infarction: an insight from survival trials.
    Yap YG; Duong T; Bland JM; Malik M; Torp-Pederson C; Køber L; Connolly SJ; Gallagher MM; Camm AJ
    J Hypertens; 2007 Feb; 25(2):307-13. PubMed ID: 17211237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial.
    Das SR; Drazner MH; Yancy CW; Stevenson LW; Gersh BJ; Dries DL
    Am Heart J; 2004 Nov; 148(5):883-8. PubMed ID: 15523322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrasting association between alcohol consumption and risk of myocardial infarction and heart failure: Two prospective cohorts.
    Larsson SC; Wallin A; Wolk A
    Int J Cardiol; 2017 Mar; 231():207-210. PubMed ID: 28043668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heart failure with preserved left ventricular systolic function among patients with non-ST-segment elevation acute coronary syndromes.
    Bennett KM; Hernandez AF; Chen AY; Mulgund J; Newby LK; Rumsfeld JS; Hochman JS; Hoekstra JW; Ohman EM; Gibler WB; Roe MT; Peterson ED
    Am J Cardiol; 2007 May; 99(10):1351-6. PubMed ID: 17493458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years.
    Buch P; Rasmussen S; Abildstrom SZ; Køber L; Carlsen J; Torp-Pedersen C;
    Eur Heart J; 2005 Jan; 26(2):145-52. PubMed ID: 15618070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relation of lower hematocrit to progression from asymptomatic left ventricular dysfunction to symptomatic heart failure (from the Studies of Left Ventricular Dysfunction Prevention trial).
    Das SR; Dries DL; Drazner MH; Yancy CW; Chae CU
    Am J Cardiol; 2005 Sep; 96(6):827-31. PubMed ID: 16169371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic importance of change in QRS duration over time associated with left ventricular dysfunction in patients with congestive heart failure: the DIAMOND study.
    Fosbøl EL; Seibaek M; Brendorp B; Torp-Pedersen C; Køber L;
    J Card Fail; 2008 Dec; 14(10):850-5. PubMed ID: 19041049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
    Fonarow GC; Stough WG; Abraham WT; Albert NM; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy CW; Young JB;
    J Am Coll Cardiol; 2007 Aug; 50(8):768-77. PubMed ID: 17707182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of location and type of myocardial infarction in the setting of advanced left ventricular dysfunction.
    Gomez JF; Zareba W; Moss AJ; McNitt S; Hall WJ
    Am J Cardiol; 2007 Mar; 99(5):642-6. PubMed ID: 17317364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO; Kashani A; Ko DK; Francis G; Krumholz HM
    Arch Intern Med; 2007 Oct; 167(18):1930-6. PubMed ID: 17923591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.